摘要
目的：观察卡维地洛(Carvedilol)治疗慢性心力衰竭(CHF)的临床疗效。方法：将80例NYHA心功能Ⅱ～Ⅳ级CHF患者随机分为两组：Carvedilol组40例,采用常规治疗(ACEI、利尿剂、血管扩张剂、有或无洋地黄)+Carvedilol；Betaloc组40例,常规治疗+Betaloc。随访1～2年,观察两组治疗前后血流动力学、左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)、6min步行距离(6-MWD)及心功能变化。结果：两组治疗后心率(HR)、收缩压(SBP)、心肌耗氧量(HR×SBP)、LVEDD、LVESD、LVEF、左室短轴缩短分数(LVFS)、NYHA心功能分级均较治疗前显著改善(P＜0．01),而Carvedilol组在血流动力学及心功能改善上较Betaloc组更明显(P＜0．05)；但治疗后组间HR降低无显著差异(P＞0．05)。两组治疗后6-MWD也均较治疗前显著增加(P＜0．01),尤其Carvedilol组(P＜0．05)。Carvedilol组无不良反应出现。结论：联用Carvedilol治疗CHF安全有效。
Objective：To observe the clinical effect of carveditol on patients with chronic heart failure （CHF）.Methods：Eighty patients with CHF （New York Heart Association [NYHA] classⅡtoⅣ） were randomly divided into two groups.Carvedilol group treated with carvedilol and stand- ard therapy for CHF （including ACEI,diuretics,vasodilator,with or without digitalis）;Betaloc group treated with betaloc in addition to the above regular therapy.All the patients were followed up for 1 to 2 years,and changes of hemodynamics,internal diameter of left ventricle,left ventricular e- jection fraction （LVEF）,6-minutes walking distance （6-MWD） and NYHA class were assessed. Results：In both groups,the heart rate （HR）,systolic blood pressure （SBP）,HR×SBP,LVEDD, LVESD,LVEF,LVFS,and NYHA class of patients all improved significantly compared with base- line measurements （P〈0.01）.The changes of hemodynamies and NYHA class in earvedilol group were more obvious than those in betaloc group （P〈0.05）,but the falling degree of the HIP,was not signif- icantly different between the two groups after treatment （P〉0.05）.The 6-MWD of patients in the two groups were increased significantly compared with pre-treatment,particularly in carvedilol group （P〈0.05）.No adverse effects related to the carvedilol were observed.Conclusions：Carvedilol combined with regular therapy might be a safe and effective way to treat CHF.
出处
《国际心血管病杂志》
2007年第1期66-68,共3页
International Journal of Cardiovascular Disease
关键词
慢性心力衰竭
卡维地洛
心功能
Chronic heart failure
Carvedilol
Cardiac function
